Pharm: parathyroid and bone Flashcards
what are the two types of bone
cortical (long bones) and trabecular (vertebral bodies, ribs, pelvis, end of long bones)
osteoclasts and osteoblasts
blasts build bone, clasts resporb
parathyroid hormone (PTH) secretion
secreted by 4 parathyroid glands - controlled by serum ionized calcium (when low, PTH stimulated)
actions of PTH
release Ca from bone, reabsorb Ca in kidneys, absorb Ca and PO4 in small intestine in order to maintain serum calcium levels
what are the 3 forms Ca circulates in?
ionized (50% - active form), protein bound calcium (albumin), complexed to bicarb, citrate, phos
what are phosphorus levels influenced by?
PTH and 1,25 (OH)2D
phosphorus reabsorption increased by
phosphate depletion, hypoparathyroidism, hypocalcemia
phosphorus excretion increased by
increased PTH, PTH4P, hypercalcemia, hypokalemia, hypomagnesemia, calcitonin, glucocorticoids and diuretics
magnesium and PTH
necessary for the release of PTH and for the action of the hormone of its target tissues
vitamin D active form
begins as biologically inert- needs 2 hydroxylations in the liver and kidney to become 25 (OH)D then active 1,25 (OH)2 D
what is the main effect of vitamin D
maintain normal serum calcium level by increasing intestinal absorption of dietary calcium and stimulating bone cells to become osteoclasts
what is renal production of 1,25 (OH)2D regulated by?
calcium levels through PTH and phosphorus
MCC hypercalcemia
hyperparathyroidism (primary - PTH is high or normal) or malignancy
also: FHH (familial hypocalcemic hypercalcemia), milk alkali syndrome, granulomatous diseases (by hydroxylation to make active vit D), medications (thiazides and lithium)
what is primary hyperparathyroidism caused by?
benign solitary adenoma 80%
4 gland hyperplasia
how is primary hyperparathyroidism diagnosed?
elevated calcium, elevated or normal PTH, low phosphorus, elevated urine calcium
what are signs and symptoms of primary hyperparathyroidism?
MOANS, GROANS, BONES, STONES, PSYCHIATRIC OVERTONES
CNS symptoms (lethargy, drowsiness, depression, confusion, coma)
neuromuscular (muscle weakness, hyporeflexia)
GI (nausea, vomiting, anorexia, constipation,)
renal (polyuria, polydipsia, impaired renal function)
cardiovascular (HTN, short QT, bradycardia)
treatment of hyperparathyroidism
cured when abnormal tissue is removed
what does PTH target?
cortical bone
when is primary hyperparathyroidism in the differential?
calcium greater than 1.0 mg/dL, creatinine clearance less than 60, age less than 50
medical treatment of primary hyperparathyroidism
- adequate hydration and ambulation
- moderate calcium intake (protect bones)
- bisphosphonates (treat low bone density)
- calcimimetics (reduce PTH and serum calcium levels by providing negative feedback)
treatment of hypercalcemia
mild (calcium less than 12) - may be asymptomatic, increase fluid intake and moderate calcium diet
moderate (12-14) intervention
severe (greater than 14) immediate treatment, poor prognosis if from malignancy
fluids for treatment of hypercalcemia
IV saline 4-6L
careful use of a loop diuretic (makes you lose Ca2+ - others don’t push out calcium) after adequate replacement to increase urinary calcium excretion and prevent volume overload
bisphosphonates for treatment of hypercalcemia
inhibit bone resportion (IV)
calcitonin for treatment of hypercalcemia
rapid effect of lowering calcium - increases urinary calcium excretion, inhibits bone resportion
-only good for acute setting (SC or IM)
corticosteroids for treatment of hypercalcemia
used in vitamin D intoxication, granulomatous diseases, and hematologic malignancies - decreases production of 1,25(OH)2D
dialysis for treatment of hypercalcemia
for those with renal failure or no response to other measures
secondary hyperparathyroidism
PTH secreted in response to a perceived low calcium concentration
what stimulates PTH secretion in secondary hyperparathyroidism?
- renal disease: phosphate retention and lack of 1-alpha hydroxylase activity in failing kidney resulting in deficient 1,25(OH)2D
- at high concentrations, phosphorus directly stimulates PTH secretion
- Vit D deficiency
how to treat secondary hyperparathyroidism as a result of vit D deficiency
replace with ergo or cholecalciferol
how to treat secondary hyperparathyroidism as a result of renal disease
low phosphate diet, phosphate binders, replacement with 1,25 vit D and dialysis
tertiary hyperparathyroidism
as a result of the parathyroid glands becoming autonomous after prolonged secondary hyperparathyroidism
how does tertiary hyperparathyroidism different from secondary?
problem lies in the gland oversecreting (like primary)
unlike secondary, serum calcium is elevated (low or normal in secondary)
hypocalcemia
parathyroid glands secrete PTH in relation to the serum calcium
- hypocalcemic disorders can arise from destruction or failure of the parathyroid glands or inactivity of PTH at target tissues
- categorized based upon low or elevated PTH levels
signs and symptoms of hypocalcemia
neuromuscular irritability (paresthesias, spasms) CNS (seizures, electroencephalographic abnormalities, increased intracranial pressure) cardiovascular (prolonged QT, heart block, CHF) abnormalities of teeth, fingernails, skin, hair
causes of hypocalcemia
hypoparathyroidism, parathyroid hormone resistance, vit D deficiency, vit d resistance, chronic renal failure, hyperphophatemia, antiresorptive agents, osteoblastic metastases, acute pancreatitis
labs for hypocalcemia
check albumin (see if calcium may actually be normal
magnesium
phosphorus levels (high in chronic renal failure)
creatinine (high in chronic renal failure)
MCC hypocalcemia
chronic renal failure - limited excretion of phosphorus and diminished hydroxylation of 1,25 vit D causes decreased calcium absorption from the cut and decreased mobilization from the bone causes PTH secretion
treatment of secondary hyperparathyroidism from CRD (chronic renal disease)
- calcitriol or other vit D analogs (paracalcitol or doxercalciferol) (oral daily or IV several tiems a week)
- phosphate binders to reduce phosphorus levels (calcium carbonate, calcium acetate, sevelamer)
- calcimimetics (cinacalcet)
hypoparathyroidism
clinical disorder when PTH produced is insufficient to maintain serum calcium levels or is unable to function properly at target tissues
-low calcium, elevated phosphorus, low PTH
25-hydroxyvitamin D as a pharmacologic agent: when used and what are teh drugs?
used in vit. d deficiency (low calcium and phosphorus, high PTH, low urine calcium)
drugs: cholecalciferol (D3) and ergocalciferol (D2)
which is more efficacious: cholecalciferol or ergocalciferol
cholecalciferol (D3)
treatment of acute hypocalcemia
calcium gluconate IV - may need vit D orally if it persists
hypophosphatemia treatment
usualyl a genetic disorder - treat by replacing phosphorus and calcitriol
treatment for osteoporosis
- bisphosphonates to reduce osteoclast bone resportion with an increase in BMD and decrease in fracture risk
include: alendronate, risedronate, ibandronate (DRONATES) - SERMS (selective estrogen receptor modulators)
include: raloxifene - calcitonin (inhibits osteoclast resorption)
- teriparatide (PTH analog)
- denosumab (RANK ligand inhibitor - antiresorptive)
side effects of bisphosphonates (DRONATES)
local GI irritation at the esophagus (need to be taken fasting in the morning) - burns holes in esophagus - need to sit up after taking
zoledronate and boniva
IV bisphosphonates given once a year (zoledronate) or every 3 months (boniva) - bypass GI tract
raloxifene
SERMs (used for osteoporosis and also breast cancer treatment)
alendronate, risdronate, ibandronate
bisphosphonates
why is calcitonin (salmon calcitonin) no longer recommended for use in osteoporosis?
cancer concerns
teriparatide
anabolic agent (building bone) for osteoporsis - PTH analog
- must be given in short bursts because blasts stimulate clasts - if short, clasts aren’t activated
- reserved for patients at high risk of fracture because of black box warning of osteosarcoma
bisphosphonates
reduce osteoclast bone resportion with an increase in BMD and decrease in fracture risk
denosumab
RANK ligand inhibitor (prevents differentiation of osteoclasts) - antiresorptive
-can be given at any GFR
side effects of denosumab
very well tolerated - skin infectiosn and hypocalcemia
paget’s disease of bone
localized disorder of bone remodeling - increase in osteoclast mediated bone resorption and in bone formation causing disorganized bone at one or more sites
complications include hearing loss, fractures, increased risk of leeding, osteosarcoma
treatment of paget’s disease
- bisphosphonates (decrease osteoclasts and impair mineralization of new bone)
includes pamidronate (3 hours), alendronate, risedronate - calcitonin
osteogenesis imperfecta
heritable disorder of type I collagen
-causes osteopenia, recurrent fractures, skeletal deformity, blue sclera
treatment of osteogenesis imperfecta
orthopedic, rehabilitative, dental interventions
-bisphosphonate therapy to prevent fracture
what is the function of calcitonin and where is it made
decrease serum calcium levels - made by C cells in the thyroid
*increases phosphate excretion like PTH (everything else is opposite PTH)
what is responsible for causing the compressive strength of bone? tensile strength?
compressive strength: hydroxyapatite (Ca, Ph, OH)
tensile strength: type I collagen
what enzyme makes active vit D?
1 alpha hydroxylase
what is PTH effect on phosphate?
increase excretion
where is phosphate reabsorbed?
proximal tubule
which malignancies cause PTHrP to raise calcium levels?
- squamous cell carcinoma of the lung
- renal cell carcinoma
- breast adenoma
- PTH levels are low/undetectable because PTHrP is not being measured and this is what is inducing the hypercalcemia
what is an example of a calcimimetic?
sensipar
phosphate binders mechanism
binds to free phosphate so that phosphate does not cause release of PTH and does not bind to calcium
labs for hypocalcemia due to chronic renal failure
phosphorus, PTH, and creatinine levels are high becuase the kidney normall excretes phosphorous and creatinine
side effects of SERMs
increased risk of endometrial cancer (estrogen decreases osteoclast activity though yay!)